InsidersTradesSigma
Track the Enovis CORP share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Enovis CORP has published 37 insider filings. Market capitalisation: €1.5bn. The latest transaction was disclosed on 16 June 2026 (Acquisition). Among the most active insiders: Engert Oliver. Every trade is free.
37
Insider Decl.
n/a
Thresholds
€411,131
12 ops.
Buy Volume
€15,567
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Enovis CORP Strong Buy (bullish), based on 11 analysts. Average price target: US$40.73.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,596 of 29,062 companies
27.0
score / 100
Value25
Quality29
FCF yld1.4%
Earn yld-84%
EV/EBITDA·
ROE-54%
Gross mgn60%
Net mgn-53%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 June 2026
Declarations37 total
1,000 sharesCommon stock, par value $0.001SEC:0001193125-26-273151:0
Canonical exit: 13 Sept 2026 (T+90)
1,000 sharesCommon stock, par value $0.001SEC:0001193125-26-271546:1
Canonical exit: 9 Sept 2026 (T+90)
200 sharesCommon stock, par value $0.001SEC:0001193125-26-271546:0
Canonical exit: 9 Sept 2026 (T+90)
1,000 sharesCommon stock, par value $0.001SEC:0001193125-26-268213:0
Canonical exit: 8 Sept 2026 (T+90)
1,000 shares@ US$23.74100.0% of flowCommon stock, par value $0.001SEC:0001193125-26-108925:0
Canonical exit: 11 Jun 2026 (T+90)
1,000 shares@ US$23.9323.1% of flowCommon stock, par value $0.001SEC:0001193125-26-104643:0
Canonical exit: 8 Jun 2026 (T+90)
143,923 shares0Common stock, par value $0.001SEC:0001193125-26-100840:0
586 shares@ US$24.5113.2% of flowCommon stock, par value $0.001SEC:0001193125-26-100846:0
2,376 shares@ US$24.5165.9% of flowCommon stock, par value $0.001SEC:0001193125-26-100845:0
2,969 shares@ US$24.5163.0% of flowCommon stock, par value $0.001SEC:0001193125-26-100844:0
1,980 shares@ US$24.5151.8% of flowCommon stock, par value $0.001SEC:0001193125-26-100843:0
1,874 shares@ US$24.5124.6% of flowCommon stock, par value $0.001SEC:0001193125-26-100842:0
3,167 shares@ US$24.5150.8% of flowCommon stock, par value $0.001SEC:0001193125-26-100841:0
250 shares@ US$24.285.9% of flowCommon stock, par value $0.001SEC:0001193125-26-100803:0
Canonical exit: 4 Jun 2026 (T+90)
1,102 shares@ US$25.7915.2% of flowCommon stock, par value $0.001SEC:0001193125-26-097150:0
765 shares@ US$25.7922.3% of flowCommon stock, par value $0.001SEC:0001193125-26-097149:0
442 shares@ US$25.7910.4% of flowCommon stock, par value $0.001SEC:0001193125-26-097148:0
3,059 shares@ US$25.7967.8% of flowCommon stock, par value $0.001SEC:0001193125-26-097147:0
2,220 shares@ US$25.7937.4% of flowCommon stock, par value $0.001SEC:0001193125-26-097146:0
888 shares@ US$25.7924.4% of flowCommon stock, par value $0.001SEC:0001193125-26-097145:0
1,173 shares@ US$25.7926.2% of flowCommon stock, par value $0.001SEC:0001193125-26-097126:0
1,000 shares@ US$24.7723.7% of flowCommon stock, par value $0.001SEC:0001193125-26-094576:0
Canonical exit: 1 Jun 2026 (T+90)
484 shares@ US$25.476.5% of flowCommon stock, par value $0.001SEC:0001193125-26-089593:0
497 shares@ US$25.4710.8% of flowCommon stock, par value $0.001SEC:0001193125-26-089592:0
889 shares@ US$25.4723.8% of flowCommon stock, par value $0.001SEC:0001193125-26-089591:0
25 of 37 declarations
关于 Enovis CORP
Enovis Corporation (NYSE: ENOV) 是一家总部位于美国的医疗技术公司，专注于骨科和康复领域。对于法语投资者而言，它符合专业健康科技工业集团的形象，拥有防御性终端市场和围绕临床差异化解决方案构建的商业模式，旨在改善患者预后并简化医疗服务提供者的工作流程。该公司的现代企业历史可追溯到1995年成立的Colfax，后来转向医疗技术领域，并最终采用Enovis的名称。其运营总部位于德克萨斯州达拉斯，商业足迹遍布全球。([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai)) Enovis的产品组合围绕两大解决方案系列。首先是重建骨科，包括髋关节、膝关节、足部和踝关节护理产品和技术，以及植入物相关系统和相邻手术解决方案。其次是康复科学与预防，包括硬性支具、骨科软性用品、血管压迫系统、冷热疗产品以及骨生长刺激器和用于疼痛管理的电刺激器等康复科学产品。这种组合使公司能够覆盖从损伤预防到术后康复的整个护理连续体。([fintel.io](https://fintel.io/doc/sec-enovis-corporation-1420800-10k-2026-february-26-20510-8732?utm_source=openai)) 从竞争角度来看，Enovis在一个由大型医疗科技公司主导的竞争激烈的全球市场中运营，但其战略建立在专业化、创新和专注于特定类别的品牌之上。其价值主张并非在于规模领先，而在于有针对性的临床效用、产品差异化以及与外科医生、医院、护理网络和患者产生共鸣的工作流程。公司的足踝、支具和康复特许经营权帮助其在需求旺盛的骨科细分市场中保持相关性。([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai)) 在地理上，Enovis拥有广泛的国际业务，在北美、欧洲和其他全球市场都有运营和销售。最近的公司发展强调了积极的投资组合管理方法：2024年初完成的LimaCorporate收购强化了其重建平台；2025年10月，公司剥离了Dr Comfort Footcare Solutions产品线；2025年7月，公司推出了Manafuse骨生长刺激器。Enovis还在AOFAS 2025上展示了新的足踝技术，包括Pecaplasty系统和其他品牌解决方案，这表明公司持续投资于创新和商业执行。([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/e/NYSE_ENOV_2023.pdf?utm_source=openai)) 简而言之，Enovis是一家在纽约证券交易所上市的美国医疗科技公司，其核心论点基于骨科专业化、康复产品以及通过收购、剥离和产品发布支持的临床差异化产品线。([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai))
